Trademark: 97922321
Word
OPDIVO QVANTIG
Status
Pending
Status Code
688
Status Date
Tuesday, December 5, 2023
Serial Number
97922321
Mark Type
4000
Filing Date
Friday, May 5, 2023
Published for Opposition
Tuesday, October 10, 2023

Trademark Owner History
Bristol-Myers Squibb Company - Owner At Publication

Classifications
5 Pharmaceutical preparations for human use for the treatment and prevention of obesity, cancer, inflammation and inflammatory diseases, auto-immune diseases, beta thalassemia and myelodysplastic syndromes, myeloproliferative diseases, myelofibrosis, leukemia, lymphoma, multiple myeloma, autoinflammatory disease, blood disease, tumors and skin diseases; Pharmaceutical preparations for human use, namely, immunosuppressants, pharmaceutical antibodies, immunotherapies for the treatment of cancer, cytokine inhibitory drugs; Pharmaceutical preparations for human use that modulate the immune system; Pharmaceutical and biological preparations for human use for immunotherapy, namely T Cell therapy; Pharmaceutical preparations for human use, namely, stem cells for medical or clinical use

Trademark Events
Dec 5, 2023
Noa E-Mailed - Sou Required From Applicant
Oct 10, 2023
Official Gazette Publication Confirmation E-Mailed
Oct 10, 2023
Published For Opposition
Sep 20, 2023
Notification Of Notice Of Publication E-Mailed
Aug 31, 2023
Approved For Pub - Principal Register
Aug 23, 2023
Teas/Email Correspondence Entered
Aug 23, 2023
Correspondence Received In Law Office
Aug 23, 2023
Teas Response To Office Action Received
Aug 2, 2023
Teas Change Of Correspondence Received
Aug 2, 2023
Applicant/Correspondence Changes (Non-Responsive) Entered
Aug 2, 2023
Teas Change Of Owner Address Received
Jun 1, 2023
Notification Of Non-Final Action E-Mailed
Jun 1, 2023
Non-Final Action E-Mailed
Jun 1, 2023
Non-Final Action Written
Jun 1, 2023
Assigned To Examiner
May 11, 2023
New Application Office Supplied Data Entered
May 9, 2023
New Application Entered

Trademark Alertz updated from USPTO on 2030-01-24